Filter Results:
(79)
Show Results For
- All HBS Web
(601)
- People (1)
- News (79)
- Research (429)
- Events (2)
- Multimedia (3)
- Faculty Publications (187)
Show Results For
- All HBS Web
(601)
- People (1)
- News (79)
- Research (429)
- Events (2)
- Multimedia (3)
- Faculty Publications (187)
←
Page 4 of 79
Results
Sort by
- 01 Mar 2010
- News
Money Matters
other policymakers to remove regulatory barriers that entangle Indian start-ups. Worse than government red tape is the lack of risk capital for emerging firms, says HBS professor Tarun Khanna, an expert on the Indian and Chinese economies... View Details
- 01 Jun 2003
- News
Books
regulation, consumer preferences, or technology change, managers in successful firms often respond with more of what worked in the past — a trap the author refers to as “active inertia.” When new realities call for new approaches, some... View Details
- 05 Aug 2016
- News
Accelerating Change on Medicine’s Final Frontier
programs that speed innovation by providing exactly what the early-stage neuroscience entrepreneurs indicate they are lacking. There are more than 200 accelerators operating worldwide, and many of them have been working with technology... View Details
Keywords: Robert S. Benchley
- 19 Feb 2020
- News
Capitol Ideas to Combat Climate Change
“You are seeing meaningful renewable programs in most states, and that’s both good news and bad news.” Using the example of her own company, a private equity firm investing in the energy sector, she explained the challenges of working within 50 different View Details
Keywords: April White; photos by Jack Conroy
- 01 Apr 2002
- News
Urban Evolution - HBS Research on the Inner City
challenge. "You have to get the price per customer per year down sufficiently low so institutions are willing to handle an account with a few hundred dollars," Tufano says. To that end, his D2D Fund has partnered with SunGard, a leading View Details
- 01 Dec 2007
- News
Where Are the Innovators in Health Care?
medical technology and health-insurance sectors, when it comes to health services, the 800-pound gorilla of our system, entrepreneurs are nowhere to be found. And their absence has enabled the status quo providers to get fat and sloppy.... View Details
- 02 Oct 2015
- News
The ‘F’ Word
information junkie, but I did generally know every answer to every nit-picking question that the higher-ups threw at me (e.g., the cost of capital at Playboy was 10 percent). I even developed a working knowledge of things as abstruse as the View Details
Keywords: Walt Disney Studios
- 24 Sep 2020
- News
The Race for a Vaccine
technology offered two advantages. First, the company had been focused on creating not a single drug, but a platform for analyzing proteins and producing synthetic mRNA. That same process could be used to analyze the proteins on a virus... View Details
- 01 Dec 2016
- News
Alumni Books of 2016
heralded for their double-digit economic growth rates, and yet, significant social and environmental fault-lines have developed in these regions. Lessem makes the case for “integral advantage,” a philosophy including nature and culture, View Details
- 01 Jun 2006
- News
The Baby Business
really is no business of stem cells yet. There’s research, and money going into research, but to date there are no products being sold on the open market. It’s a fledgling business. The other major difference has to do with the regulatory... View Details
- 01 Sep 2005
- News
WATER Ltd.
to outsource water treatment because of its increasing complexity and strict regulatory requirements. Industrial water treatment is a capital-intensive industry, so that tends to drive it into the hands of large multinationals.” Indeed,... View Details
- 11 May 2017
- News
Going with the Flow
launch of WaterRev, an investment company that focuses on novel technologies which enable sustainable practices of water use. In 2012, she joined the board of the Boston Beer Company, producer of Samuel Adams, Angry Orchard, and other... View Details
Keywords: Robert S. Benchley
- 01 Dec 2013
- News
Your Own Medicine
dollars. All told, the process takes about 10 to 15 years. "I think we're all frustrated, we're all disappointed," explains PhRMA's EVP of scientific and regulatory affairs Bill Chin, former executive dean for research at Harvard Medical... View Details
- 01 Dec 2008
- News
A Force for Good
in particular, received steady, low-key infusions of technology and volunteer time — spearheaded by faculty members like Jim Cash, but backed steadfastly by the Dean’s Office. “But John didn’t want the newspaper story,” Menino emphasizes.... View Details